Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mevalonic acid metabolic intermediate product in preparation of medicines for improving aging ovarian oocyte quality and meiosis process

A technology of mevalonate and oocytes, applied in the field of bioengineering, can solve problems such as unclear

Inactive Publication Date: 2021-04-20
NANJING DRUM TOWER HOSPITAL
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

FOH is also used as a raw material for vitamin synthesis drugs, which can induce apoptosis in a variety of tumor cell lines, so its derivatives have become candidate anticancer drugs, but whether it can improve ovarian aging in oocytes as an intermediate product of MVA metabolism cell mass, still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mevalonic acid metabolic intermediate product in preparation of medicines for improving aging ovarian oocyte quality and meiosis process
  • Application of mevalonic acid metabolic intermediate product in preparation of medicines for improving aging ovarian oocyte quality and meiosis process
  • Application of mevalonic acid metabolic intermediate product in preparation of medicines for improving aging ovarian oocyte quality and meiosis process

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] This example provides a drug that can improve the quality of aging ovarian oocytes and the progress of meiosis. The drug is an in vitro maturation medium containing 10 μmol / L geranylgeraniol (GGOH), and its components are shown in the table 1.

[0046] Table 1 Composition of in vitro maturation medium containing GGOH

[0047] Element volume / mass Final concentration BSA 0.12g 3mg / mL Streptomycin Mixture 400μL FSH 5μL 50IU / L LH 5μL 10IU / L sodium pyruvate 100μL 0.23 mmol / L Glutamine 400μL 2mmol / L M199 39.082mL GGOH stock solution dissolved in absolute ethanol (50 mmol / L) 8μL 10μmol / L final volume 40mL

[0048] Applying this GGOH-containing in vitro maturation medium to improve the quality of aging ovarian oocytes and the progress of meiosis, the addition mode and experimental process are as follows: figure 1 Shown:

[0049] (1) 10-month-old C57BL / 6 female mice were intraperiton...

Embodiment 2

[0060] This example provides a drug that can improve the quality of aging ovarian oocytes and the progress of meiosis. The drug is an in vitro maturation medium containing 20 μmol / L farnesol (FOH), and its components are shown in Table 2 .

[0061] Table 2 Composition of in vitro maturation medium containing FOH

[0062] Element volume / mass Final concentration BSA 0.12g 3mg / mL Streptomycin Mixture 400μL FSH 5μL 50IU / L LH 5μL 10IU / L sodium pyruvate 100μL 0.23 mmol / L Glutamine 400μL 2mmol / L M199 39.074mL FOH stock solution dissolved in absolute ethanol (50mmol / L) 16μL 20μmol / L final volume 40mL

[0063] Application of this FOH-containing in vitro maturation medium to improve aging ovarian oocyte quality and meiotic progression:

[0064] (1) 10-month-old C57BL / 6 female mice were intraperitoneally injected with 10IU PMSG, and the mice were killed by neck dislocation 48 hours later. Th...

Embodiment 3

[0074] This example provides a drug that can improve the quality of aging ovarian oocytes and the progress of meiosis. The drug is an absolute ethanol injection preparation dissolved in geranylgeraniol (GGOH). The preparation method is to dissolve GGOH Prepare a 50mmol / L GGOH stock solution in absolute ethanol, which is the GGOH absolute ethanol solution injection preparation.

[0075] Application of this GGOH absolute ethanol solution injection preparation improves aging ovarian oocyte quality and meiotic progression:

[0076] (1) 9-month-old C57BL6 mice were divided into two groups, the control group (absolute ethanol solution) and the GGOH administration group (GGOH absolute ethanol solution injection preparation), administered at 18:00 every day, according to 40mg / kg The body weight was taken from the injection preparations of the control group and the GGOH group, diluted 10 times with sterile normal saline, and injected intraperitoneally, and administered continuously for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a mevalonic acid metabolic intermediate product in preparation of medicines for improving aging ovarian oocyte quality and meiosis process. The mevalonic acid metabolic intermediate product is geranyl geraniol or farnesol. One medicine is an in-vitro maturation culture medium containing the mevalonic acid metabolic intermediate product, the first polar body emission rate of mature oocytes can be significantly increased, and the abnormal rate of meiosis can be reduced. The other medicine is an absolute ethyl alcohol injection preparation with the dissolved mevalonic acid metabolic intermediate product, ovary weight, ovary indexes and the number of follicles at all levels can be remarkably increased, the PB1 emission rate of oocytes is remarkably increased after administration, and the chromosome / spindle abnormal rate of MII oocytes of superovulation and COCs in-vitro maturation is remarkably reduced.

Description

technical field [0001] The invention belongs to the technical field of bioengineering and relates to the application of mevalonate metabolic intermediates in the preparation of medicines for improving the quality of aging ovarian oocytes and the progress of meiosis. Background technique [0002] Women's ovarian function generally begins to decline from the age of 35, mainly manifested in a decrease in the number of follicles and a decrease in the quality of oocytes. The fertility problems of older women have attracted more and more attention. Chromosomal abnormalities in oocytes of advanced women with age increase are the main reasons for the decrease in pregnancy rate and increase in miscarriage. During the process of meiosis, aging oocytes are more prone to chromosomal lag and premature sister chromatid segregation. The proportion of aneuploid and triploid female oocytes was significantly increased. Previous studies have shown that drugs that improve mitochondrial functio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/045A61P15/00
Inventor 丁利军李朝军孙海翔刘传明
Owner NANJING DRUM TOWER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com